PMID- 7686456
OWN - NLM
STAT- MEDLINE
DCOM- 19930803
LR  - 20190909
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 19
IP  - 3
DP  - 1993 Mar
TI  - N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, 
      reverses the inhibitory effect of insulin on lipolysis due to dibutyryl cyclic 
      AMP.
PG  - 177-81
AB  - The effects of several calmodulin antagonists on the antilipolytic activity of 
      insulin were studied in isolated rat adipocytes. 
      N-(6-aminohexyl)-5-Chloro-1-naphthalenesulfonamide (W-7) antagonized the 
      inhibitory effect of insulin on lipolysis due to dibutyryl cyclic AMP (Bt2cAMP) 
      (0.5 mM), but not due to adrenaline (1 microM) or 3-isobutyryl-1-methylxanthine 
      (IBMX) (0.1 mM). The concentration of W-7 required for half-maximal suppression 
      of antilipolytic effect of insulin (25 microU/ml) was 12 microM. High 
      concentrations (up to 1000 microU/ml) of insulin could not overcome this 
      suppression by W-7. W-7 did not affect the insulin binding to its receptor on fat 
      cells. Other types of calmodulin antagonists such as trifluoperazine or 
      calmidazolium did not antagonize the inhibitory effect of insulin. These findings 
      show that the insulin receptor or calmodulin may not be involved in this 
      suppressive effect of W-7.
FAU - Goko, H
AU  - Goko H
AD  - School of Allied Medical Sciences, Kobe University, Japan.
FAU - Matsuoka, A
AU  - Matsuoka A
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Calmodulin)
RN  - 0 (Imidazoles)
RN  - 0 (Insulin)
RN  - 0 (Insulin Antagonists)
RN  - 0 (Sulfonamides)
RN  - 214IZI85K3 (Trifluoperazine)
RN  - 4R9H38JAWL (calmidazolium)
RN  - 63X7MBT2LQ (Bucladesine)
RN  - 65595-90-6 (W 7)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - TBT296U68M (1-Methyl-3-isobutylxanthine)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - 1-Methyl-3-isobutylxanthine/pharmacology
MH  - Adipose Tissue/drug effects/*metabolism
MH  - Animals
MH  - Bucladesine/*pharmacology
MH  - Calmodulin/*antagonists & inhibitors
MH  - Cells, Cultured
MH  - Dose-Response Relationship, Drug
MH  - Epididymis
MH  - Epinephrine/pharmacology
MH  - Imidazoles/pharmacology
MH  - Insulin/metabolism/*pharmacology
MH  - Insulin Antagonists/*pharmacology
MH  - Kinetics
MH  - Lipolysis/*drug effects
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Insulin/drug effects/metabolism
MH  - Sulfonamides/*pharmacology
MH  - Trifluoperazine/pharmacology
EDAT- 1993/03/01 00:00
MHDA- 1993/03/01 00:01
CRDT- 1993/03/01 00:00
PHST- 1993/03/01 00:00 [pubmed]
PHST- 1993/03/01 00:01 [medline]
PHST- 1993/03/01 00:00 [entrez]
AID - 0168-8227(93)90111-H [pii]
AID - 10.1016/0168-8227(93)90111-h [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 1993 Mar;19(3):177-81. doi: 
      10.1016/0168-8227(93)90111-h.